Pnuemocystis jirovecii pneumonia (PJP) is one of leading causes of acute respiratory failure in patients infected with human immunodeficiency virus (HIV), and the mortality rate remains high in mechanically ventilated HIV patients with PJP. There are several reported cases who received extracorporeal membrane oxygenation (ECMO) treatment for respiratory failure associated with severe PJP in HIVinfected patients. We report a patient who was newly diagnosed with HIV and PJP whose condition worsened after highly active antiretroviral therapy (HAART) initiation and progressed to acute respiratory distress syndrome requiring veno-venous ECMO. The patient recovered from PJP and is undergoing treatment with HAART. ECMO support can be an effective life-saving salvage therapy for acute respiratory failure refractory to mechanical ventilation following HAART in HIV-infected patients with severe PJP.
A 59-year-old Korean man was admitted to a local general hospital with a 4-day history of fever, dry cough, and progressive dyspnea on exertion. Chest radiography on admission showed bilateral patchy increased radiopacity (Fig. 1A) , and chest computed tomography revealed diffuse ground-glass opacities with a mosaic pattern (Fig. 1B) .
Because rapid HIV antibody testing was positive, pneumonia caused by an atypical pathogen such as Pneumocystis jirovecii or cytomegalovirus (CMV) was suspected, and the patient was transferred to our institution. He had lost 10 kg body weight during the previous year and had felt sick for a month. He was a former 20-pack-year smoker with heavy alcohol consumption (more than three alcoholic beverages per week). He had had sexual encounters with men during his 50s. On arrival, he was conscious but appeared acutely ill. Blood pressure was 110/70 mmHg, heart rate 116 beats/ min, respiratory rate 26 breaths/min, and body temperature 38.8°C. The initial laboratory evaluation revealed a white Fig. 1 . Chest radiograph and computed tomography. Chest radiography and computed tomography images were obtained on hospital days 1 (A, B), 6 (C), and 19 (D, E). A and B. Chest radiographs show increased patchy opacities, and chest computed tomography reveals diffuse ground-glass opacities with a mosaic pattern in both lungs on admission. C. Chest radiography reveals mild improvement of the ground-glass density in both lungs after TMP/SMX therapy with corticosteroids on hospital day 6. D and E. Aggravated diffuse consolidation and ground-glass opacities were noted on chest radiograph and computed tomography on hospital day 19 
Discussion
Cases of ECMO support for refractory respiratory failure in HIV-infected patients during PJP treatment have rarely been reported in the literature. [8] [9] [10] The characteristics of the patients including our case are presented in Table 1 . Other conditions, including pulmonary co-infection by other organisms, progressive disease due to poor compliance, and
All cases had a baseline CD4 T-cell count of less than
Pneumocystis organisms' potential resistance to TMP/SMX were also considered. [16, 17] patients, and intravenous therapy is generally recommended for those with moderate to severe PJP.
[17] As an alternative regimen, clindamycin and primaquine can be selected for patients who fail to respond to or develop toxicity with TMP/SMX. [19] Due to severe nausea to oral and intravenous TMP/ SMX, our patient's PJP therapy was changed to clindamycin and primaquine at the time of HAART administration. Paradoxical deterioration with ARDS improved with the change in PJP therapy to intravenous TMP/SMX, as well as ECMO support. Similarly, patient 3 [10] was started on intravenous pentamidine as a first-line regimen due to reported allergy to TMP/ SMX. Shortly before ECMO initiation, intravenous TMP/ SMX was administered through a desensitization procedure.
Treatment failure with the accepted regimen is uncommon;
however, there was indeed a temporal connection between respiratory decompensation and alteration of the therapeutic regimen for PJP, as well as HAART initiation.
This case report provides an opportunity to address the use of ECMO in patients with HIV infection. ECMO is usually not recommended in patients with significant preexisting comorbidities or those who are immunocompromised due to poor outcomes. [20] A high mortality rate has been reported in mechanically ventilated HIV-infected patients with severe PJP, [6, 7] for whom ECMO support may seem to be medically futile. The RESP score was developed to predict survival after ECMO initiation from patients receiving ECMO for severe acute respiratory failure and comprised 12 simple preECMO variables including immunocompromised status.
[12] The RESP score of our case was -2, correlating with a survival of only 33% and ARDS presentation requiring Tae-Hyung Kim
